Gain Therapeutics (GANX) Return on Invested Capital (2021 - 2025)
Historic Return on Invested Capital for Gain Therapeutics (GANX) over the last 5 years, with Q3 2025 value amounting to 3.79%.
- Gain Therapeutics' Return on Invested Capital fell 17400.0% to 3.79% in Q3 2025 from the same period last year, while for Sep 2025 it was 3.79%, marking a year-over-year decrease of 17400.0%. This contributed to the annual value of 2.07% for FY2024, which is 6600.0% down from last year.
- Latest data reveals that Gain Therapeutics reported Return on Invested Capital of 3.79% as of Q3 2025, which was down 17400.0% from 3.68% recorded in Q2 2025.
- Over the past 5 years, Gain Therapeutics' Return on Invested Capital peaked at 0.2% during Q2 2021, and registered a low of 3.79% during Q3 2025.
- Moreover, its 5-year median value for Return on Invested Capital was 1.69% (2023), whereas its average is 1.6%.
- In the last 5 years, Gain Therapeutics' Return on Invested Capital crashed by -17600bps in 2023 and then soared by 3700bps in 2024.
- Quarter analysis of 5 years shows Gain Therapeutics' Return on Invested Capital stood at 0.38% in 2021, then crashed by -125bps to 0.86% in 2022, then tumbled by -159bps to 2.22% in 2023, then fell by -14bps to 2.53% in 2024, then crashed by -50bps to 3.79% in 2025.
- Its last three reported values are 3.79% in Q3 2025, 3.68% for Q2 2025, and 3.13% during Q1 2025.